We draw upon decades of collective, scientific, & drug-development experience to address very high unmet needs of patients and bring improved health to patients
We are developing
#RLF100
for treatment of
#COVID19
-related Acute Respiratory Distress (
#ARDS
) in partnership with Relief Therapeutics.
Read more in Pharmaceutical Technology:
Today we announced promising data from a cohort of patients with Critical
#COVID19
who received our investigational drug aviptadil (
#RLF100
) under the U.S. FDA Expanded Access Protocol.
Learn more:
Today we announced initial results of 72% survival in our ongoing open label Expanded Access Program for patients with Critical
#COVID19
receiving SOC and treated with our investigational drug aviptadil (
#RLF100
).
Read the press release:
NRx has validated the first commercial formulation of its medicine for Critical
#COVID
-19, allowing for high volume manufacture, as potential regulatory approvals are obtained. Read more in the press release here:
Today we announced having met the target enrollment of 165 patients in our Phase 2b/3
#clinicaltrial
of aviptadil (
#RLF100
) for Critical
#COVID19
.
Read the press release:
Today we shared additional data on ZYESAMI™ (aviptadil) showing a 10 day accelerated recovery from respiratory failure among patients with Critical
#COVID19
treated with high flow nasal oxygen.
Learn more:
.
@CDCgov
has reported over 300,000 new
#COVID19
cases in the last 7 days. With cases on the rise, the need for effective treatments is greatly emphasized.
Follow our journey at
More COVID-19 stats from the CDC:
#aviptadil
Aviptadil (
#RLF100
) is thought to protect against Critical
#COVID19
by binding to the Alveolar Type II lung cells that are targeted by
#SARSCoV2
.
Learn more about the MOA and follow our journey at
#aviptadil
Yesterday, the Data Monitoring Committee (DMC) voted unanimously that our study of
#aviptadil
(RLF-100™) in Critical
#COVID
-19 patients should continue as planned. Follow our journey at
Read more:
Today we announced the submission of our request for Emergency Use Authorization for aviptadil (
#RLF100
) in patients with Critical COVID-19 who who have exhausted all approved treatments:
Follow our journey:
NeuroRx is one of only four companies to receive Fast Track Designation from the FDA for an investigational drug to treat Critical
#COVID19
. Follow our NeuroRx journey to develop aviptadil (
#RLF100
):
Learn more about Fast Track:
Today we announced that we have enrolled 150 patients (out of a targeted enrollment of 165) in our ongoing Phase 2b/3 trial of
#RLF100
in Critical
#COVID19
.
Read the press release:
We are pleased to announce the inclusion of ZYESAMI™ (RLF-100™: aviptadil) in the I-SPY COVID-19 Trial which will allow us to gather data on the use of inhaled aviptadil for Critical
#COVID19
.
Learn more:
Yesterday we announced our request for an Emergency Use Authorization from the FDA for the use of
#RLF100
(aviptadil). Read more about it from
@PHLBizJGeorge
via
@PHLBizJournal
.
Few effective drug options exist for
#COVID19
induced Acute Respiratory Distress Syndrome (
#ARDS
). We're committed to addressing this unmet need as quickly as possible. Follow our journey to develop
#RLF100
for Critical COVID-19 with respiratory failure.
“For the most part, people who die of
#COVID
die of respiratory distress. So we’ve developed a drug that specifically attacks that mechanism by which COVID kills people.” See Dr. Javitt,
#NeuroRx
CEO, discuss
#ZYESAMI
on
#FoxBusiness
.
#clamancountdown
Our CEO Dr. Jonathan Javitt recently sat down with
@RfwrightLSL
of Life Science Leader and a panel of biopharma CEOs including
@PeterDiamandis
to discuss
#COVID19
technologies in development and our work with
#RLF100
.
Watch the roundtable:
ZYESAMI™ is the first medicine to show efficacy in a randomized, double-blind, multicenter trial, achieving more instances of recovery in critically ill
#COVID
-19 patients with respiratory failure, compared to placebo.
#DYK
: NeuroRx has Fast Track designation from the FDA for our clinical trial of Aviptadil (
#RLF100
), allowing us to progress with our investigational treatment as quickly as possible.
Learn more about our journey and our study:
“We look forward to working with the FDA in hopes of providing critically ill patients with a new medicine that will increase their chances of recovery, enabling them to leave the hospital and return to their families significantly sooner.” - Jonathan Javitt, MD CEO of NRx
Today we announced the completion of our agreement with Relief Therapeutics covering the global commercialization of Aviptadil. NeuroRx is leading the commercialization in the US, Canada & Israel, and Relief in Europe and the rest of the world.
NeuroRx is committed to the clinical development of aviptadil (
#RLF100
) to help patients suffering from Critical
#COVID19
respiratory failure breathe freely again.
Follow our journey at
#RCWeek20
CEO Dr. Jonathan Javitt joined a panel of experts at the World Leading Hospitals conference to discuss the challenges of drug development during
#COVID19
and our development of aviptadil (
#RLF100
) for COVID-19.
Panel at 43:26 and interview at 2:23:24:
CEO Dr. Jonathan Javitt recently sat down with
@Jerusalem_Post
to discuss our progress with aviptadil (
#RLF100
) and NeuroRx’s unique history and culture.
Learn more about our journey:
NRx Pharmaceuticals has submitted an application to the FDA requesting Emergency Use Authorization for ZYESAMI™ (Aviptadil-acetate) to treat Critically Ill COVID-19 patients suffering respiratory failure. Learn more at:
We have established supply chain agreements and ordered Aviptadil (
#RLF100
) drug substance to potentially treat 1 million patients with
#COVID19
, should the pandemic continue and our studies prove successful.
Learn more:
#aviptadil
Aviptadil (
#RLF100
), our drug in development for Critical
#COVID19
respiratory failure, is a synthetic form of human Vasoactive Intestinal Peptide. Though still in clinical trials, promising data have been reported in our EAP open label study.
Learn more:
NeuroRx CEO Dr. Jonathan Javitt and COO & Head of Operations Robert Besthof recently sat down with
@MoeAlsumidaie
of
@Clin_Trials
to discuss the challenges of developing
#COVID19
therapies and our work with ZYESAMI™ (previously RLF-100™: aviptadil):
Gain scientific insight into the mechanisms that underlie our investigational drug
#Aviptadil
(
#RLF100
) and its potential to treat critical
#COVID19
and other life-threatening pulmonary conditions.
Read the pre-print on
@Authorea
:
Our team excels at rapid advancement of already-known molecules as potentially lifesaving solutions.
#Aviptadil
(
#RLF100
) went from an idea in March to drug on-site in mid May 2020.
Learn more and follow us:
Dr. Fauci highlighted ZYESAMI's new clinical trial with
@NIH
in Friday's briefing from the White House coronavirus task force.
ICYMI: ZYESAMI will be studied alone and in combination with remdesivir for treating severely ill COVID patients.
NRx Pharmaceuticals announced a new partnership that has the best for patients in mind. Click here to read our press release about efforts to develop an inhaler for respiratory conditions.
Today we announced a feasibility collaboration with
@TFFPharma
in order to identify an optimal long-term stable formulation of ZYESAMI™ for
#COVID19
.
Learn more:
The
@BioRender
#COVID19
Vaccine & Therapeutics tracker features the development progress of COVID-19 therapeutics and an activity feed with live updates on their advancements.
Check out our drug in development, aviptadil (
#RLF100
):
Our CEO Dr. Jonathan Javitt spoke with
@RfwrightLSL
about how we turned a 10-year-old drug into a promising drug in development for the treatment of critical
#COVID19
in just 10 weeks.
Watch now on Life Science Leader:
#RLF100
#aviptadil
🔊 NeuroRx CEO Dr. Jonathan Javitt discussed vaccine rollouts, COVID therapeutics and more on
@Cheddar
!
"Unless we're vigilant to also develop COVID therapeutics; unless we have a way to decrease the lethal effects of COVID, just vaccinating everybody is not going to be enough."
At NeuroRx, we pride ourselves on our ability to be nimble as an organization and rapidly shift our focus to areas of the utmost need. We went from concept to clinic in 10 weeks for our Critical
#COVID19
study of aviptadil.
Learn more about our values:
Tune in to the Disease Control and Prevention Summit today at 10:10 am EST and hear Dr. Jonathan Javitt present new data regarding aviptadil's impact on the "cytokine storm" in patients suffering
#COVID19
. Watch live here:
We target very severe conditions, and our team of experienced pharma executives is uniquely equipped to develop known molecules in a new and efficient way.
Learn about our culture and follow the development of aviptadil (
#RLF100
) for Critical
#COVID19
:
NRx Pharmaceuticals, Inc. (NRx) is now a public company, trading as NRXP on the
@Nasdaq
Global Select Exchange. We invite you to learn more about our efforts here:
#nasdaq
#MarketNews
CEO Dr. Jonathan Javitt looks ahead to one of biopharma’s biggest challenges in
#2021
: tackling the
#COVID19
pandemic.
Read more industry insight from Dr. Javitt and other biopharma executives in
@PharmaScrip
:
Hundreds of Americans and thousands around the world are dying from COVID-19, many from respiratory failure. Medicines are urgently needed. Newly-formed $NRXP is focused on bringing first in class medicines to patients struggling to take a breath.
#COVID19
Tune in to the Disease Control and Prevention Summit on July 21st at 10:10 am EST to see and hear CEO of NRx, Dr. Jonathan Javitt present new data regarding aviptadil's impact on the "cytokine storm" in patients suffering
#COVID19
. Watch here:
.
@NeuroRxPharma
is excited to announce a new clinical trial of ZYESAMI for the treatment of severely ill COVID-19 patients with Acute Respiratory Distress Syndrome. ZYESAMI will be evaluated alone and in combination with remdesivir.
These past weeks the US has seen a record number of
#COVID19
hospitalizations and deaths, and conditions continue to worsen. Learn more about our efforts to develop aviptadil (
#RLF100
) for Critical COVID-19 at .
More from
@nytimes
:
NeuroRx Pharma CEO Dr. Jonathan Javitt recently spoke with industry veterans
@AlokTayi
and
@RahulC
about our development of ZYESAMI™ (
#RLF100
, aviptadil) on the
@Biotech2050Pod
podcast.
Listen now:
The World Health Organization’s Coronavirus dashboard offers an interactive, global overview of the
#COVID19
pandemic. As cases increase in the US and other countries, the need for therapeutics is greater than ever.
More from the
@WHO
:
CEO Dr. Jonathan Javitt spoke with
@BioSpace
about the recently announced Phase 2b/3 data for ZYESAMI™ (
#aviptadil
) and how we will continue to advance the development of our investigational
#COVID19
drug.
Read it here:
CEO Dr. Jonathan Javitt recently sat down with
@EdClinical
of
@ClinicalLeader1
to discuss NeuroRx’s unique history and how our culture helps us accelerate the development of much needed therapies.
Learn more:
Today we announced that our CEO Dr. Jonathan Javitt will present a company overview at the
@SoleburyTrout
Fall Private Company Showcase.
Join us tomorrow at 9 AM ET:
Read the press release:
CEO Dr. Jonathan Javitt recently sat down with
@BioPharmaMike
on
@DRGInsights
’ “Conversations in Healthcare” series to discuss our overall plans for aviptadil (
#RLF100
) and some data of patients in our Expanded Access (open label) study.
Watch now:
The Georgian Ministry of Health today agreed to an expanded access program for ZYESAMI.
We're eager to deliver this lifesaving drug to critically ill COVID-19 patients in Georgia, the Caucasus region and beyond.
Learn more:
CEO Dr. Jonathan Javitt recently sat down with
@thequeenmuse1
of
@phillymag
to discuss NeuroRx’s unique history, our focus on the development of drugs for some of the most severe conditions, and our roots in the greater Philadelphia area.
Learn more:
Vaccines for COVID-19 are crucial, but they are only part of the solution. Medicines to help
#COVID
patients recover from this virus are very much in need. Follow NRx to learn how we are addressing unmet needs in treating COVID-19.
“As variants continue to evolve, the likelihood that some will bypass the vaccine and create another surge, tells us that the need for therapeutics remains high.” - Dr. Jonathan Javitt, MD CEO of NRx on the need for more medicines to treat
#COVID
-19.
In line with our mission to focus on areas of very high unmet need, we are pleased to announce that we have received a notice of patent allowance from the
@USPTO
for our formulation for the treatment of post-traumatic stress disorder
#PTSD
.
Learn more:
Yesterday we announced our Agreement and Plan of
#Merger
with Big Rock Partners Acquisition Corp. This is an important step in our journey to develop much needed therapies for Critical
#COVID19
, bipolar depression and more.
Read the press release:
This week is Respiratory Care Week, an important week of advocating for patients and supporting
#RespiratoryTherapists
. In the midst of
#COVID19
, respiratory care is more vital than ever.
Learn how you can get involved in
#RCWeek20
from
@AARC_tweets
:
#COVID19
has also had an impact on mental health across the world. Through our development of ZYESAMI (
#RLF100
) for Critical COVID-19 and NRX-100/101 for bipolar
#depression
, we have programs focused on two of the highest unmet medical needs.
More:
Learn more about our development of ZYESAMI (Aviptadil,
#RLF
-100) for Critical
#COVID19
, our clinical programs, and merger with Big Rock Acquisition Corp. in
@GENBio
.
More from
@AlexWestchester
:
NRx Chairman and CEO Jonathan Javitt will be speaking at the
@LongwoodFund
Healthcare Leaders web con Oct 4-5 with fellow biopharma CEOs, the Head of the FDA, Gov Baker, and top academics.
You can join the meeting here:
#longwoodhealthcareleaders
NRx Pharmaceuticals defies the traditional pharma industry paradigm. Our scientific expertise lets us move rapidly to research and develop already-known molecules and deliver lifesaving solutions.
Today we reported Initial Phase 2b/3 study results for ZYESAMI™ (aviptadil) in patients with respiratory failure due to critical
#COVID19
.
Learn more:
“It’s a 65-million-year-old molecule that's seeing its first shot in a randomized controlled trial.” NRx CEO, Dr. Jonathan Javitt on Bloomberg Radio yesterday announcing NRx as a publicly traded company, highlighting ZYESAMI and NRx-101 trials and more.
From suicidal depression to Critical
#COVID19
, we have always focused on patients with the highest unmet need.
Watch CEO Dr. Jonathan Javitt explain the origins of NeuroRx on
@DRGInsights
’ “Conversations in Healthcare” with
@BioPharmaMike
:
We are excited about our plan to merge with Big Rock Partners Acquisition Corp., a critical part of our journey to develop treatments for patients with very high unmet needs.
Learn more about our plan of merger:
NeuroRx’s culture of dedication and urgency uniquely positions us to develop much needed therapies in areas of very high unmet need, including critical
#COVID19
. Watch our CEO Dr. Jonathan Javitt discuss the hurdles we are overcoming to develop Aviptadil:
NRx Pharmaceuticals is dedicated to our mission of “Bringing Hope to Life” through development of innovative medicines for life-threatening, unmet medical needs.
By creating therapies where none exist, we put the patient at the center of everything we do.
NRx extends its ongoing Phase 2/3 trial of inhaled ZYESAMI™ to Nation of Georgia, in partnership with Denk Pharma (Georgia), and Cromos, LLC.
See full details at:
#COVID19
Physicians in the Nation of Georgia will be trained in emergency use of intravenous ZYESAMI™ for patients suffering Critical COVID-19.
See the full press release here:
#COVID19
This trial will be carried out across the country in partnership with
@NIAIDNews
and
@nih_nhlbi
, as part of
@NIH
's Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) research agenda. For more information:
There are no approved medicines to treat people with bipolar disorder. NRx Pharmaceuticals is developing the first investigational medicines for this acute mental illness. Follow us to stay informed.
#MentalHealthAwarenessMonth
NRx Pharmaceuticals, Inc. today announced that it has filed a new Breakthrough Therapy designation request with the FDA focused on a subgroup of patients with Critical COVID-19 that in addition to aviptadil or placebo were also treated with remdesivir.